Glanz Jason, France Eric, Xu Stan, Hayes Taru, Hambidge Simon
Institute for Health Research, Kaiser Permanente Colorado, PO Box 378066, Denver, CO 80237-8066, USA.
Pediatrics. 2008 Mar;121(3):e506-12. doi: 10.1542/peds.2007-1129.
The objective of this study was to identify risk factors for developing chronic idiopathic thrombocytopenic purpura in a cohort of pediatric patients with idiopathic thrombocytopenic purpura.
We conducted a retrospective cohort analysis of 259 children who were diagnosed with idiopathic thrombocytopenic purpura between 1991 and 2000 at 1 of 8 managed care organizations that comprise the Vaccine Safety Datalink. We reviewed the charts of 595 potential patients with idiopathic thrombocytopenic purpura from the 8 Vaccine Safety Datalink sites and excluded patients with known causes of thrombocytopenia. Chronic idiopathic thrombocytopenic purpura was defined as having thrombocytopenia for 6 months beyond the initial diagnosis. The risk for developing chronic idiopathic thrombocytopenic purpura was assessed using simple and multivariable analyses.
Of the 259 cases of idiopathic thrombocytopenic purpura, 197 (76%) were acute, 60 (23%) were chronic, and 2 (1%) could not be determined. Among the acute cases, the mean duration of illness was 22 days. There was 1 serious bleeding outcome in the cohort. In multivariable regression analysis, the patients with chronic illness were older, less likely to present with mucosal bleeding, less likely to have had an acute illness before diagnosis, and more likely to present with a platelet count > 20,000/microL than children with acute idiopathic thrombocytopenic purpura. In particular, children whose illness was diagnosed at > or = 10 years of age and who had platelet counts > or = 20,000/microL had an approximate fivefold risk for progressing to chronic disease when compared with children who presented at < or = 2 years of age with platelet counts < 20,000/microL.
Although idiopathic thrombocytopenic purpura tends to be a benign and self-limited condition, acute and chronic idiopathic thrombocytopenic purpura seem to be distinct illnesses defined by age, platelet count, bleeding symptoms, and the presence of acute illness before diagnosis. Physicians should be aware of these differences when advising their patients and families.
本研究的目的是在一组患有特发性血小板减少性紫癜的儿科患者中确定发生慢性特发性血小板减少性紫癜的危险因素。
我们对1991年至2000年间在组成疫苗安全数据链的8个管理式医疗组织之一被诊断为特发性血小板减少性紫癜的259名儿童进行了回顾性队列分析。我们查阅了来自8个疫苗安全数据链站点的595名潜在特发性血小板减少性紫癜患者的病历,并排除了已知血小板减少原因的患者。慢性特发性血小板减少性紫癜定义为在初次诊断后血小板减少持续6个月以上。使用单变量和多变量分析评估发生慢性特发性血小板减少性紫癜的风险。
在259例特发性血小板减少性紫癜病例中,197例(76%)为急性,60例(23%)为慢性,2例(1%)无法确定。在急性病例中,平均病程为22天。队列中有1例严重出血结局。在多变量回归分析中,与急性特发性血小板减少性紫癜儿童相比,慢性病患者年龄较大,出现黏膜出血的可能性较小,诊断前患急性病的可能性较小,血小板计数>20,000/微升的可能性较大。特别是,与2岁及以下血小板计数<20,000/微升的儿童相比,10岁及以上诊断疾病且血小板计数≥20,000/微升的儿童进展为慢性病的风险约为五倍。
尽管特发性血小板减少性紫癜往往是一种良性的自限性疾病,但急性和慢性特发性血小板减少性紫癜似乎是由年龄、血小板计数、出血症状以及诊断前是否存在急性病所定义的不同疾病。医生在为患者及其家属提供建议时应意识到这些差异。